As practicing clinicians and scientists, keeping up with the literature poses many challenges in our hectic lives. The ongoing demands of our professional responsibilities continue to increase, and our time to peruse journals and read the literature has decreased. In addition, the number of journals continues to rise, and the multidisciplinary nature and intricacies of medical research, which may require additional learning to get up to speed, continue to expand. Given these demands, it is still important for us to critically read journal articles, and in doing so, we must determine the clinical and scientific merits of the study. Although there are many factors to consider when gauging the scientific merit of a study, one that is critically important is to fully understand the authors' financial conflicts of interest (COIs) prior to reading any article.
Consider the following 5 scenarios: (1) an investigator obtains funding from an orthopaedic company to perform a study related to its commercial products, (2) a clinicianscientist receives donated surgical equipment from a commercial entity to support a research study, (3) a physician is granted unrestricted funds from a commercial entity to help support his or her laboratory or educational mission, (4) a research team obtains support from a private foundation or patient advocacy group, and (5) a principal investigator acquires a highly competitive grant from the National Institutes of Health (NIH) to support his or her research program. Do all of these scenarios represent a COI? Is it possible to rank order the conflicts?
So, what is the definition of a financial COI? One that is frequently cited was posited by Thompson. 26 It refers to ''a set of conditions in which professional judgment concerning a primary interest (such as a patient's welfare or the validity of research) tends to be unduly influenced by a secondary interest (such as financial gain).'' 26 The secondary interest could be in the form of research support directly related to the study, unrestricted research funds, consultant fees, stipends, royalty payments, and/or stock options directly or indirectly from commercial sources. This is true whether the company is well established or even if it is a virtual company aimed at translating a novel technology to future clinical use. Furthermore, a COI is frequently categorized as ''actual'' or ''potential.'' An actual COI exists when financial considerations have the potential to bias professional judgment and objectivity, while a potential COI exists if the results of a study could develop into an actual COI after publication. McCoy and Emanuel 15 recently presented the valid argument, however, that ''labeling certain COI as merely 'potential' or 'perceived' diminishes their seriousness and obscures the ethical rationale for trying to limit COI in medical practice and research.' ' We are in a time in which government investment in biomedical and health care research continues to diminish. In the United States, further reductions to the NIH budget have been proposed and may still be on the horizon. Thus, research support from the commercial sector is required to continue the advancement of health care. In 2012, it was reported that the total funding for biomedical research in the United States was $116.5 billion, 58% of which was supported by medical device, biotechnology, and pharmaceutical firms, up approximately 30% since 1994. 16 The value of company-sponsored research has also been highlighted by the NIH, which encourages partnerships between the public and private sectors 27 (eg, the Osteoarthritis Initiative, the Small Business Technology Transfer funding mechanism). Possessing a COI is not in itself unethical, and it only implies a potential for bias. 17 Thus, companysponsored research should not be automatically assigned a lower quality rating without a careful evaluation, which requires full transparency of the authors' COIs. Prior studies evaluating the impact of COIs on the interpretation of study results have reported mixed findings, 4, 11, 13, 22, 23 with some studies showing that the quality of a manuscript with a commercial COI is downgraded by the physician reading the article, while other studies have shown no change. To the best of my knowledge, this type of analysis has not yet been reported for orthopaedic practitioners.
The effects of industry support in biomedical research have been evaluated. A systematic review, published in 2003, determined that approximately one-quarter of all investigators in biomedical research had industry affiliations, two-thirds of the academic institutions held equity in start-up companies, and industry sponsorship increased the likelihood of positive conclusions. 2 Surgery in 2014, only 18% of the articles listed COIs, and it was determined that the articles with COIs were not more likely to report a positive outcome; in fact, the opposite was found. 7 These studies provide interesting insight into the potential effects of investigators' COIs on biasing outcomes in orthopaedic research. However, there are confounding factors that could have influenced the interpretation of these studies, as they are based on self-reported COIs. Also, it is likely that bias is introduced because industry may be more apt to fund studies with high expectations of success and that industry-funded studies with negative results may be less likely to be published. Nonetheless, these studies highlight the need to consider COIs when critically reading an article.
Although COIs are prevalent in company-sponsored research, a discussion of COIs in government-and foundation-funded research is warranted. 14, 20 The livelihoods of many academic researchers are dependent on government (eg, NIH, National Science Foundation) and foundation funding (eg, Arthritis Foundation). In academic institutions, continued funding of investigators via these extramural sources ensures job security, promotion, and tenure. 20 Strong publication records, particularly manuscripts that present positive outcomes, improve the odds of successfully obtaining a government-sponsored research grant. Furthermore, the overarching goal of orthopaedic researchers supported by government funding is to develop new treatment strategies for the improvement of orthopaedic care. In order to translate these new strategies, companies need to be involved or formed. Other ''non-financial conflicts,'' which include personal beliefs, pride, academic competition, and societal perceptions, 3, 20 also introduce bias and are ultimately intertwined with financial success. Likewise, there is also a potential for COIs in research supported by private foundations and patient advocacy groups. McCoy et al 14 determined that 83% of the 104 largest patient advocacy groups received financial support from industry. Listing government and/or foundation support is important for transparency, but the personal demands (ie, tenure review, promotional status, job security) on the investigator remain unknown from the disclosure. Nevertheless, it is important to appreciate that a COI is a factor to consider when evaluating studies supported by public or foundation grants.
While many readers of the literature may jump to conclusions regarding the negative impact of companysponsored research, 24 there are benefits. The different perspectives brought together through academic-industry partnerships enhance our understanding of disease mechanisms, enable the discovery of novel applications for existing products, and expedite the development of new therapeutics. 1 Academic-industry partnerships are essential for the translation of research to clinical use. Given the decrease in government grant funding, industry funding provides alternative sources to keep academic laboratories running. Surprisingly, recent studies have shown that 75% to 80% of the general public and patients do not perceive financial relationships between industry and orthopaedic surgeons as a problem; however, most thought that the disclosure of COIs to the patient was necessary. 6, 28 While it is evident that these partnerships might increase the potential for bias, the benefits and societal implications of these partnerships are clear if the conflict is properly managed.
The need to address COIs in medicine is not new and continues to evolve. In 1984, the New England Journal of Medicine initiated a policy in which all articles were required to disclose sources of funding. 29 The following year, the AAOS required presenters to disclose COIs, 29 a policy that was adopted by the American Orthopaedic Society for Sports Medicine (AOSSM). In the current issue of the AJSM, there are 28 articles. Of these, 10 reported no conflicts, 8 received funding from commercial parties, 7 were federally/nationally funded, 2 reported foundation support, and 1 received internal hospital support. Of the 8 listing commercial ties, only 3 appear to be related to the topic of the manuscript. Currently, the AJSM disclosure policy (http://ajsm-submit.highwire.org/journals/amjsports/forms/ Author_Disclosure.doc) exceeds the standards set by the International Committee of Medical Journal Editors (ICMJE), 8 and the AJSM board continues to refine this policy. 21, 22 The prevalence of COIs of editorial board members has also been noted. 9 Across the 5 major spine journals, it was determined that only 22% of the editorial board members had nothing to disclose. 9 Seven of the 8 editors of the AJSM declared COIs, which are publicly available via the web (http://journals.sagepub.com/page/ajs/editor-disclosures). The AJSM reviewer database also includes the self-reported COIs of potential reviewers to help filter out conflicts when review assignments are made by the editors. If asked to do a review, it is essential for potential reviewers to carefully evaluate their personal conflicts (both financial and nonfinancial) to determine if one exists before accepting the review and to let the editorial staff know about the conflict to update the database.
Complete transparency is critical to the proper presentation of research, and it is the responsibility of the authors to provide full disclosure. The current COI policies for the AJSM are based on the honesty of the authors when selfreporting disclosures. As a rule of thumb, it is best to list all ''potential'' conflicts as COIs (actual or perceived). It is also my opinion that company-sponsored papers should clearly state their support in the Methods section. COIs are managed through self-reporting; however, there is evidence indicating that the self-reporting mechanism is not adequate. 10, 19, 25 In the study by Okike et al, 19 it was determined that 28% of the participants of the AAOS 2008 annual meeting failed to disclose their conflicts; the most frequent reasons cited for oversight were that the ''payment was unrelated to the topic of presentation'' or ''the physician had misunderstood the disclosure requirements.'' When filling out a disclosure form, it is always best to list a conflict if one is unsure; more than likely, it could be perceived as a conflict. Even if no conflict was perceived, no harm would be done in disclosing the relationship. If there was a case in which a COI was not properly disclosed, the journal would follow the guidelines of the Committee on Publication Ethics (COPE). 5 A correction would be published once the discrepancy was discovered. If, for some reason, there was the appearance that an author intentionally hid a conflict, the issue would be referred to the ethics committee of the AJSM editorial board to consider additional options.
It is clear from a review of the recent literature on the management of COIs for biomedical research that researchers, journals, institutions, and funding agencies have not reached a consensus on the best way to manage conflicts. The lack of agreement is most likely due to the subjectivity and complexity required to balance conflict management without holding back scientific progress. 1 It is clear, however, that transparency is vital. Revisiting the 5 scenarios described above, it is clear that an argument could be made that all of these scenarios represent a financial COI. As far as rank ordering the potential bias, it must be left to the reader of the study, armed with the information contained in the disclosure, to determine if the level of bias is acceptable in his or her mind.
In summary, all government-, nonprofit-, and industrysupported research involves some degree of COI. Having a COI is not unethical, and as authors, we need to provide full and open disclosure. It is best to err on disclosing something that may not be directly applicable than to miss something that is. As reviewers, we need to be cognizant of our own COI to ensure that it does not conflict with papers or grants that we are asked to review. As readers of the literature, it is important to be cautious and aware of the authors' COIs upfront when evaluating the strengths and weaknesses of a study.
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